<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Basic principles of bone grafts and bone substitutes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Basic principles of bone grafts and bone substitutes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Basic principles of bone grafts and bone substitutes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Katherine Sage, MS, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">L Scott Levin, MD, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy S Colwell, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amalia Cochran, MD, FACS, FCCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3484019052"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Bone grafts fill bony voids or gaps of the skeletal system that may be the result of surgically created osseous defects (eg, tumor resection), related to osteonecrosis, or the result of trauma.</p><p>Bone grafting is commonly used in multiple surgical specialties including orthopedic surgery, neurosurgery, plastic surgery, and dental surgery. Almost two million bone grafting procedures are performed worldwide per year [<a href="#rid1">1</a>]. In the United States, over 500,000 bone graft procedures are performed annually, making bone grafts second only to blood transfusion as the most common tissue transplantation [<a href="#rid2">2</a>].</p><p>This topic will review the properties and categories of bone grafts and the basic principles of their use. </p><p class="headingAnchor" id="H653414368"><span class="h1">BONE GRAFT CHARACTERISTICS</span><span class="headingEndMark"> — </span>Bone grafts are described based on their properties and clinical features. Based upon their properties, bone grafts may be regarded by the US Food and Drug Administration as drugs, a device, or a combination drug/device with appropriate regulation depending on the category  (<a class="graphic graphic_table graphicRef134490" href="/d/graphic/134490.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H1178232092"><span class="h2">Bone graft properties</span><span class="headingEndMark"> — </span>Bone grafts have one or more of the following properties that describe the actions of the bone graft [<a href="#rid3">3-5</a>]. These include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteoconductivity</strong> – Osteoconductive materials provide a structural framework for bone growth.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteoinductivity</strong> – Osteoinductive materials contain factors that stimulate bone growth through upregulation of osteoprogenitor cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteogenicity</strong> – Osteogenic materials directly provide cells such as mesenchymal stem cells, osteoblasts, or osteocytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteostimulation </strong>– Osteostimulative materials upregulate expression of osteogenic genes or proteins by mesenchymal stem cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bioactivity</strong> – Bioactive materials form a layer of bone-like mineral on their surface, which is proposed to aid the process of osteointegration. </p><p></p><p class="headingAnchor" id="H2527671032"><span class="h2">Bone graft features</span><span class="headingEndMark"> — </span>Another way to assess bone graft characteristics is through the graft's material features, which include porosity, resorption rate, origin, handling properties and physical features, ability to mix, immunogenicity, and composition [<a href="#rid5">5</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Porosity</strong> – Pore size and shape for bony incorporation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Origin</strong> – The origin of the graft, such as autograft (from the patient), allograft (human donor), xenograft (from nonhuman donor), and synthetic (manmade).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resorption rate </strong>– This describes how quickly a bone graft is resorbed by the human body. For example, autograft resorbs more quickly than anatomic bone growth. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Handling properties and physical features</strong> – Grafts come in liquid or flowable forms, granules of various sizes, putties, strips, and on conduits such as sponges, among other formulations. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ability to mix</strong> – Some grafts can be mixed with blood, platelet-rich plasma, or bone marrow aspirate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunogenicity</strong> – Immunogenicity describes how the body reacts to a bone graft. This includes potential disease transmission, an inflammatory response, or immunomodulation to promote healing. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Composition</strong> – Allografts contain cells. Synthetic grafts may contain silicate or bioglass. Bone morphogenic protein includes proteins. </p><p></p><p class="headingAnchor" id="H1007257019"><span class="h1">CATEGORIES OF BONE GRAFT</span></p><p class="headingAnchor" id="H376519286"><span class="h2">Autograft</span><span class="headingEndMark"> — </span>Autograft bone is the gold standard of bone graft. Autograft can be nonvascularized such as with cancellous bone, cortical bone, and bone marrow aspirate, or the bone graft can be harvested with a feeding artery (ie, vascularized bone graft). The immunogenic response to autograft is typically very low. However, drawbacks include limited blood supply with nonvascularized bone grafts and donor site morbidity, which is more prominent with vascularized bone grafts [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H3119084587"><span class="h3">Nonvascularized bone grafts</span></p><p class="headingAnchor" id="H3996431364"><span class="h4">Bone marrow aspirate</span><span class="headingEndMark"> — </span>Bone marrow aspirate involves retrieving cells from the bone marrow, which is rich in mesenchymal stem cells and growth factors [<a href="#rid6">6</a>]. Limitations include the lack of osteoconductive properties, so it is often mixed with a carrier. Benefits include cost and osteogenic cells. Common sources include the anterior or posterior pelvis and the proximal or distal fibula.</p><p class="headingAnchor" id="H4219518201"><span class="h4">Cancellous bone</span><span class="headingEndMark"> — </span>Cancellous bone is the most commonly used form of autologous bone grafting because it is prevalent throughout the body and relatively easy to harvest [<a href="#rid7">7,8</a>]. Limitations include less structural support compared with cortical bone. High volumes of cancellous bone can be harvested with the use of a reamer/irrigator/aspirator. Often, cancellous bone is harvested near the surgical site, such as from the vertebrae for spine surgery, or the tibia, femur, or distal radius with extremity surgery.</p><p class="headingAnchor" id="H1626039376"><span class="h4">Cortical bone</span><span class="headingEndMark"> — </span>Cortical bone offers structural integrity. However, there is lower incorporation due to limited cellularity and healing through creeping substitution [<a href="#rid7">7,8</a>]. There is also the risk of donor site morbidity, for example meralgia paresthetica, which is an injury to the lateral femoral cutaneous nerve that can occur when harvesting iliac crest cortical bone graft [<a href="#rid9">9</a>]. Common sources include the anterior or posterior wing of the iliac crest.</p><p class="headingAnchor" id="H2367472647"><span class="h3">Vascularized bone grafts</span><span class="headingEndMark"> — </span>Vascularized bone grafts harvest the nutrient, metaphyseal, and/or additional perforating vessels to transfer with the bone graft. Benefits include the transfer of vascular supply, osteoprogenitor cells, and cortical and cancellous bone. This is technically challenging [<a href="#rid7">7,8</a>]. Common sources for vascularized bone grafts include the distal radius (based on the 1 to 2 intercompartmental super-retinacular artery branch of radial artery), a free fibular strut graft (based on the peroneal artery), or the free iliac crest graft (based on the deep circumflex iliac artery).</p><p class="headingAnchor" id="H1345896266"><span class="h2">Extenders to autografts</span><span class="headingEndMark"> — </span>The use of some materials potentially allows less<strong> </strong>autograft to be harvested, with the aim of decreasing the risk of donor site morbidity and pain [<a href="#rid10">10</a>]. As an example, allograft, demineralized bone matrix, or synthetic agents may be added as extenders to iliac crest autograft bone in surgical situations that require a higher volume of bone graft.</p><p>When a product is cleared by the US Food and Drug Administration as an "extender," this refers specifically to its use as an extender to autograft in the surgeon's hands. Some products do not require the surgeon to perform this function. In addition, there may be competing products within the same category with the same composition (particularly in synthetics) that have different indications from the FDA (ie, as an extender, as a standalone, or both) because some manufacturers will make the appropriate application, but others will not. </p><p class="headingAnchor" id="H3036377445"><span class="h2">Allograft</span><span class="headingEndMark"> — </span>Allograft is bone obtained from a human donor and that may be processed using a variety of techniques. The three types of bone allograft (fresh, fresh frozen, and freeze dried) have differing properties [<a href="#rid2">2,8,11</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Fresh allograft is washed but not sterilized of all cells and therefore has the highest risk of disease transmission or immune response of the allograft categories. The benefit is that it is osteoinductive. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fresh frozen undergoes more thorough cleaning, but still retains the osteoinductive properties. There is less of a risk of disease transmission. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Freeze dried is the least immunogenic, with the lowest risk of immunogenicity, but it is purely osteoconductive. Treatment is via ethanol wash with or without gamma irradiation.</p><p></p><p class="headingAnchor" id="H1865171413"><span class="h3">Demineralized bone matrices</span><span class="headingEndMark"> — </span>Demineralized bone matrices (DBMs) are processed allografts that have undergone several phases of acid treatment and rinsing to remove the inorganic phases of bone and to deactivate biological contaminants such as viruses.​ The benefits include availability in many formations and are not as expensive as other categories. Limitations include variation of osteoconductive and osteoinductive properties between products and lot-to-lot, sterilization may inactivate or attenuate osteoinductive factors, and immunogenicity [<a href="#rid8">8,11,12</a>].</p><p class="headingAnchor" id="H224273210"><span class="h3">Cell-based allografts/matrices</span><span class="headingEndMark"> — </span>Cell-based allografts contain native bone cells such as mesenchymal stem cells, osteoblasts, or pre-osteoblasts. The cells are kept alive by the addition of a cryoprotectant and freezing for storage. Cell-based matrices (CBMs) often also consist of a combination of cancellous allograft chips and/or DBM. ​Benefits include osteogenic properties and availability in a variety of formulations. Limitations include cost, risk of disease transmission, donor-dependent variation in efficacy, and need for an optimized infrastructure for freezing and thawing. In June 2021, the FDA issued a recall for a widely used cell-based allograft contaminated with tuberculosis [<a href="#rid11">11,13-20</a>].</p><p class="headingAnchor" id="H2946256500"><span class="h2">Xenografts</span><span class="headingEndMark"> — </span>Xenografts are a category of bone graft that is obtained from a nonhuman species. Coralline, obtained from marine coral, was first used in the 1970s as a bone graft substitute. Since that time, it has been combined with hydroxyapatite and used as a synthetic/xenograft bone graft combination [<a href="#rid21">21</a>]. (See <a class="local">'Hydroxyapatite'</a> below.) </p><p>Similarly, bovine bone is frequently used as an osteoconductive scaffold in allograft bone grafts [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H2843259087"><span class="h2">Synthetic ceramic grafts</span><span class="headingEndMark"> — </span>Synthetic ceramic grafts are artificially produced, not made from human tissue, and may be used as a standalone graft or an extender to autograft depending on their regulatory category [<a href="#rid10">10</a>]. </p><p class="headingAnchor" id="H285090790"><span class="h3">First-generation</span><span class="headingEndMark"> — </span>First-generation synthetic materials include calcium sulfate, hydroxyapatite, beta tricalcium phosphate, and biphasic calcium phosphate. </p><p class="headingAnchor" id="H1254098656"><span class="h4">Calcium sulfate</span><span class="headingEndMark"> — </span>Calcium phosphate, also known as "Plaster of Paris," was first used in the late 19<sup>th</sup> century to fill large bony defects. Calcium sulfate resorbs through chemical dissolution at a rate that is faster than the anatomic rate of bone resorption. Because of its cement-like structure, it can be used to fill large bony defects [<a href="#rid23">23</a>].</p><p>In clinical practice, surgeons may mix calcium sulfate with an antibiotic powder (eg, <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a>) to make antibiotic beads, which can be packed into infected bone to provided extended treatment; the antibiotic continues to release as the beads dissolve. In some countries, this may be "off-label" use. Proprietary absorbable calcium sulfate antibiotic carrier products are also available. </p><p class="headingAnchor" id="H3595191182"><span class="h4">Hydroxyapatite</span><span class="headingEndMark"> — </span>Hydroxyapatite (HA) has been in use since the 1950s as a xenograft combined with sea coral (<a class="drug drug_general" data-topicid="9185" href="/d/drug information/9185.html" rel="external">calcium carbonate</a>) or bovine bone. Subsequently, synthetic HA was produced in the 1970. HA has high chemical stability and a very slow resorption rate, which may impair assessment of radiological fusion and/or impair the rate of bone healing. The benefits of HA include low cost, variety of formulations, and good porosity [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H3617304046"><span class="h4">Beta tricalcium phosphate</span><span class="headingEndMark"> — </span>Beta tricalcium phosphate (B-TCP) was first used as a bone graft in the 1980s. Like HA, this is available in a wide variety of formulations including granules, putties, and strips, can be manufactured with a range of porosity, and is cost effective. B-TCP is more degradable than HA; however, it does have an unpredictable biodegradation profile [<a href="#rid25">25-27</a>].</p><p class="headingAnchor" id="H1423455979"><span class="h4">Biphasic calcium phosphate</span><span class="headingEndMark"> — </span>Biphasic calcium phosphate (BCP) is a mix of HA and B-TCP and therefore has an intermediate resorption profile, which can be manipulated based on the ratio of HA to B-TCP. It has been in use in the US since the 1990s. BCP is available in a wide variety of formulations including granules, putties, and strips; can be manufactured with a range of porosity; and is cost effective [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H2192798588"><span class="h3">Second-generation</span><span class="headingEndMark"> — </span>Second-generation synthetics include silicated calcium phosphate and bioglass.</p><p class="headingAnchor" id="H1974246740"><span class="h4">Silicated calcium phosphate</span><span class="headingEndMark"> — </span>Silicated calcium phosphate (Si-CaP) is an ion-substituted calcium phosphate that entered the market in the US in the 2000s. Scientists substituted small amounts of silicate ions (&lt;1 percent) for phosphate ions. Research suggests that silicate enhances bioactivity with increased activity and differentiation of bone cells in vitro, as well as faster bone ingrowth in vivo, although this has not translated into improved outcomes in human clinical studies. Many Si-CaPs are HA products, which have a slow resorption profile. As with the first-generation synthetics, this is available as granules, putties, or strips and has a wide range of porosity. It is more expensive that first-generation synthetics [<a href="#rid28">28-31</a>].</p><p class="headingAnchor" id="H1086577643"><span class="h4">Bioglass</span><span class="headingEndMark"> — </span>Bioglass contains silica, sodium, calcium, and phosphorus and is similar to glass. It entered the market in the 2000s. The ion release from bioglass can increase activity and differentiation of bone cells in vitro, can be osteoconductive by creating a calcium phosphate surface layer, and may have antibacterial effects. There have been reports of immunogenic reactions. It is available as granules, putties, or strips and is more expensive than first-generation synthetics [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H258646758"><span class="h3">Advanced</span><span class="headingEndMark"> — </span>Advanced synthetics use enhanced surface topography to create bony ingrowth.</p><p class="headingAnchor" id="H723643381"><span class="h4">BCP &lt;1 micrometer</span><span class="headingEndMark"> — </span>The submicron needle-shaped surface of BCP &lt;1 micrometer polarizes macrophages into a pro-healing M2 phenotype. The M2 macrophages are then able to cross-talk with mesenchymal stem cells, inducing an immune response that stimulates osteoprogenitor cells to form bone. BCP &lt;1 micrometer has grown bone in muscular pouches without additional cells or growth factors in animal models and has proved equivalent to autograft in validated, clinically relevant sheep models [<a href="#rid33">33,34</a>]. Level 1 human trials are in progress.</p><p class="headingAnchor" id="H108628388"><span class="h4">Microporous BCP</span><span class="headingEndMark"> — </span>Microporous BCP is a TCP with surface topography that has been shown to form bone in intramuscular sites. There have been reports of resorption leading to nonunion [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H2227481735"><span class="h2">Growth factors</span><span class="headingEndMark"> — </span>Depending on their FDA regulation class, growth factors can be used standalone or as extenders to bone grafts (eg, autograft, xenograft).</p><p class="headingAnchor" id="H3138122965"><span class="h3">Peptides (P-15)</span><span class="headingEndMark"> — </span>One xenograft of bovine bone is enhanced with synthetic peptide P-15 adsorbed to its surface. The peptide P-15 contains the cell-binding domain of collagen and modulates binding, activity, and osteogenic differentiation of bone cells that interact with the graft after implantation [<a href="#rid36">36,37</a>]. The instructions for use state "Peptide Enhanced Bone Graft must be used inside an allograft bone ring and with supplemental anterior plate fixation" [<a href="#rid38">38</a>]. </p><p class="headingAnchor" id="H1307670305"><span class="h3">Bone morphogenetic proteins</span><span class="headingEndMark"> — </span>Recombinant human bone morphogenetic proteins (BMPs) are growth factors that must be combined with an osteoinductive carrier. BMP is an extender, but it is provided in a kit from the manufacturer so that the surgeon doesn't need to perform this function before implantation. BMPs signal to mesenchymal stem cells to initiate bone formation. Limitations include cost, as well as reported complications with on-label use, including ectopic bone formation [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H4081153827"><span class="h3">Platelet-derived growth factor</span><span class="headingEndMark"> — </span>Recombinant human platelet-derived growth factor is a recruiter of mesenchymal stem cells and an up-regulator of angiogenesis. This is mixed with B-TCP for osteoconductivity [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H2864303524"><span class="h1">CLINICAL USES</span><span class="headingEndMark"> — </span>Bone grafting is commonly used in multiple specialties including orthopedic surgery, neurosurgery, plastic surgery, and dental surgery [<a href="#rid2">2,41-47</a>]. Within these fields, common surgical applications for bone grafts include filling bony voids that result from:</p><p class="bulletIndent1"><span class="glyph">●</span>Elective arthrodesis surgery</p><p class="bulletIndent1"><span class="glyph">●</span>Traumatic injury</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor resection</p><p class="bulletIndent1"><span class="glyph">●</span>Debridement for fracture nonunion or osteomyelitis</p><p class="bulletIndent1"><span class="glyph">●</span>Cancellous bony voids caused by avascular necrosis</p><p></p><p class="headingAnchor" id="H2066905582"><span class="h2">Selection</span><span class="headingEndMark"> — </span>Since the options for bone grafting are many and without robust comparison data, the selection of one category over another is based on anatomic and patient factors and the experience and preference of the surgeon. Any of the bone grafts described above may be used to manage any bone defect, although the application in certain situations may be "off label." Factors limiting use include availability (eg, autograft), cost (eg, bone morphogenetic protein), or lack of evidence for efficacy for a particular application. </p><p class="headingAnchor" id="H1229658703"><span class="h2">Clinical scenarios</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elective arthrodesis surgery</strong> – Filling bony voids for arthrodesis (ie, bone fusion) differs depending on anatomic location. For some anatomic regions (eg, carpal bones in the wrist, tibiotalar joint, tarsal and metatarsal joints in the foot), once the articular cartilage is removed, the gap between the bleeding cancellous bones that results is minimal (typically &lt;5 mm) and easily filled, resulting in a favorable healing environment. By comparison, fusion involving the spine is more difficult because the gap that results following disc removal is large.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malunion and nonunion of fractures</strong> – Determining the type of nonunion can help direct bone graft usage in revision surgery. By definition, hypertrophic nonunions have adequate bone biology but inadequate stability in fixation; oligotrophic nonunions may have adequate bone biology but have inadequate reduction of the bony fragments; and atrophic nonunions have inadequate bone biology. As such, considering the type of nonunion and the adequacy of the native bone anatomy can direct the bone graft choice, bearing in mind that the hardware and fixation methods are also of paramount importance in these cases [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/d/html/13798.html" rel="external">"General principles of fracture management: Early and late complications", section on 'Nonunion and malunion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteomyelitis</strong> – Bone graft substitutes can be used to provide local antimicrobial therapy. In a systematic review evaluating the effectiveness of antimicrobial bone graft substitutes in the treatment of osteomyelitis, primary and secondary outcomes from 15 observational studies were promising, with high clinical success rates at short-term follow-up [<a href="#rid49">49</a>]. The rates of eradication of infection varied from 80 to 100 percent, bone growth rates varied from 87.5 to 100 percent, and the bone graft substitute degradation was 100 percent in all studies except for one. However, the quality of the studies was overall low. (See  <a class="medical medical_review" href="/d/html/114350.html" rel="external">"Nonvertebral osteomyelitis in adults: Treatment"</a> and  <a class="medical medical_review" href="/d/html/7663.html" rel="external">"Vertebral osteomyelitis and discitis in adults", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extremity reconstruction after trauma</strong> – Because of the variability in fracture patterns, soft tissue injury associated with fracture, vascularity surrounding long bones, and healing patterns of long bones, axial skeleton, and extremities, there are no clear best practices when choosing a bone graft in trauma. Autograft from of iliac crest is widely selected as the standard; however, surgeons must make a case-by-case decision when choosing which bone graft, if any, to use for each individual fracture scenario [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/16527.html" rel="external">"Surgical reconstruction of the upper extremity"</a> and  <a class="medical medical_review" href="/d/html/15121.html" rel="external">"Surgical reconstruction of the lower extremity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reconstruction after tumor resection</strong> – Bony defects from malignant tumor resection can represent a challenging reconstructive problem. The most commonly used bone grafts for these cases include allografts, vascularized fibular grafts, extracorporeally devitalized autograft, or segmental bone transplant [<a href="#rid51">51</a>]. (See  <a class="medical medical_review" href="/d/html/16527.html" rel="external">"Surgical reconstruction of the upper extremity"</a> and  <a class="medical medical_review" href="/d/html/15121.html" rel="external">"Surgical reconstruction of the lower extremity"</a> and  <a class="medical medical_review" href="/d/html/109432.html" rel="external">"Surgical management of chest wall tumors"</a> and  <a class="medical medical_review" href="/d/html/111809.html" rel="external">"Surgical management of severe rib fractures"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avascular osteonecrosis</strong> – The pathology of avascular necrosis relates to a failure of blood supply to nourish the bony environment, and as such, some authors advocate prioritizing a vascularized bone graft for reconstruction of these defects to restore viable bone, provide structural support, and re-establish blood supply [<a href="#rid52">52</a>]. (See  <a class="medical medical_review" href="/d/html/5613.html" rel="external">"Treatment of nontraumatic hip osteonecrosis (avascular necrosis of the femoral head) in adults"</a> and  <a class="medical medical_review" href="/d/html/5919.html" rel="external">"Acute and chronic bone complications of sickle cell disease", section on 'Osteonecrosis (avascular necrosis)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posterolateral spine fusion</strong> – Fusion rates vary widely for the differing bone graft categories when applied to posterolateral spinal fusion (PLF) [<a href="#rid10">10,26,27,32,35,39,53-56</a>]. This is due in part to variability in techniques used for PLF and quality of the various studies, as well as the established difficulty of PLF specifically when compared with fusion procedures at other anatomic sites [<a href="#rid25">25</a>]. </p><p></p><p class="headingAnchor" id="H3779662418"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120396.html" rel="external">"Society guideline links: Severe blunt or penetrating extremity trauma"</a> and  <a class="medical medical_society_guidelines" href="/d/html/122571.html" rel="external">"Society guideline links: General fracture and stress fracture management in adults"</a>.)</p><p class="headingAnchor" id="H3741276356"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone grafting</strong> – Bone grafting is commonly used in multiple surgical specialties to fill voids or gaps of the skeletal system that may be related to trauma, osseous defects created during surgery (eg, tumor resection), or the result of osteonecrosis. The type of bone graft used for filling a bony void depends upon the disease process, anatomic location, and size of the defect. (See <a class="local">'Introduction'</a> above and <a class="local">'Clinical uses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Characteristics of bone grafts</strong> – Bones grafts are characterized by one or more properties (eg, osteoconductivity, osteoinductivity, osteogenicity, osteostimulation, bioactivity) or other features (eg, origin, porosity, absorption rate, formulation, composition, mixability, immunogenicity). (See <a class="local">'Bone graft characteristics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone graft categories</strong> – Bone grafts can be derived from human (eg, autograft, allograft) or animal (ie, xenograft) tissues or be manmade (ie, synthetic; eg, hydroxyapatite, beta tricalcium phosphate, biphasic calcium phosphate, silicated calcium phosphate). Bone grafts can originate from cancellous or cortical bone and transferred in part, or in total, as nonvascularized or vascularized grafts. Allografts may be processed prior to implantation to reduce their immunogenicity. (See <a class="local">'Categories of bone graft'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone graft extenders</strong> – Extenders potentially allow less autograft to be harvested, with the aim of decreasing the risk of donor site morbidity. These may include but are not limited to growth factors, peptides, and bone morphogenetic proteins. (See <a class="local">'Extenders to autografts'</a> above and <a class="local">'Growth factors'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Campana V, Milano G, Pagano E, et al. Bone substitutes in orthopaedic surgery: from basic science to clinical practice. J Mater Sci Mater Med 2014; 25:2445.</a></li><li><a class="nounderline abstract_t">Baldwin P, Li DJ, Auston DA, et al. Autograft, Allograft, and Bone Graft Substitutes: Clinical Evidence and Indications for Use in the Setting of Orthopaedic Trauma Surgery. J Orthop Trauma 2019; 33:203.</a></li><li><a class="nounderline abstract_t">Campion CR, Ball SL, Clarke DL, Hing KA. Microstructure and chemistry affects apatite nucleation on calcium phosphate bone graft substitutes. J Mater Sci Mater Med 2013; 24:597.</a></li><li><a class="nounderline abstract_t">Albrektsson T, Johansson C. Osteoinduction, osteoconduction and osseointegration. Eur Spine J 2001; 10 Suppl 2:S96.</a></li><li><a class="nounderline abstract_t">Hing KA. Bone repair in the twenty-first century: biology, chemistry or engineering? Philos Trans A Math Phys Eng Sci 2004; 362:2821.</a></li><li><a class="nounderline abstract_t">McCarrel T, Fortier L. Temporal growth factor release from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression. J Orthop Res 2009; 27:1033.</a></li><li><a class="nounderline abstract_t">Indrawattana N, Chen G, Tadokoro M, et al. Growth factor combination for chondrogenic induction from human mesenchymal stem cell. Biochem Biophys Res Commun 2004; 320:914.</a></li><li><a class="nounderline abstract_t">Roberts TT, Rosenbaum AJ. Bone grafts, bone substitutes and orthobiologics: the bridge between basic science and clinical advancements in fracture healing. Organogenesis 2012; 8:114.</a></li><li><a class="nounderline abstract_t">Murata Y, Takahashi K, Yamagata M, et al. Injury to the lateral femoral cutaneous nerve during harvest of iliac bone graft, with reference to the size of the graft. J Bone Joint Surg Br 2002; 84:798.</a></li><li><a class="nounderline abstract_t">Morris MT, Tarpada SP, Cho W. Bone graft materials for posterolateral fusion made simple: a systematic review. Eur Spine J 2018; 27:1856.</a></li><li><a class="nounderline abstract_t">James AW, LaChaud G, Shen J, et al. A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2. Tissue Eng Part B Rev 2016; 22:284.</a></li><li><a class="nounderline abstract_t">Bae H, Zhao L, Zhu D, et al. Variability across ten production lots of a single demineralized bone matrix product. J Bone Joint Surg Am 2010; 92:427.</a></li><li><a class="nounderline abstract_t">Russell N, Walsh WR, Lovric V, et al. In-vivo Performance of Seven Commercially Available Demineralized Bone Matrix Fiber and Putty Products in a Rat Posterolateral Fusion Model. Front Surg 2020; 7:10.</a></li><li class="breakAll">Trinity Evolution instructions for use. https://www.orthofix.com/wp-content/uploads/2019/01/Trinty-Evolution-IFU.pdf (Accessed on December 06, 2021).</li><li><a class="nounderline abstract_t">Herrmann M, Hildebrand M, Menzel U, et al. Phenotypic Characterization of Bone Marrow Mononuclear Cells and Derived Stromal Cell Populations from Human Iliac Crest, Vertebral Body and Femoral Head. Int J Mol Sci 2019; 20.</a></li><li><a class="nounderline abstract_t">Siddappa R, Licht R, van Blitterswijk C, de Boer J. Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. J Orthop Res 2007; 25:1029.</a></li><li><a class="nounderline abstract_t">Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 2014; 32:252.</a></li><li><a class="nounderline abstract_t">Skovrlj B, Guzman JZ, Al Maaieh M, et al. Cellular bone matrices: viable stem cell-containing bone graft substitutes. Spine J 2014; 14:2763.</a></li><li><a class="nounderline abstract_t">Hsieh PC, Buser Z, Skelly AC, et al. Allogenic Stem Cells in Spinal Fusion: A Systematic Review. Global Spine J 2019; 9:22S.</a></li><li class="breakAll">FDA 2021 Biologics Recalls https://www.fda.gov/vaccines-blood-biologics/recalls-biologics/2021-biologics-recalls (Accessed on December 01, 2021).</li><li><a class="nounderline abstract_t">Demers C, Hamdy CR, Corsi K, et al. Natural coral exoskeleton as a bone graft substitute: a review. Biomed Mater Eng 2002; 12:15.</a></li><li><a class="nounderline abstract_t">Cohen JD, Kanim LE, Tronits AJ, Bae HW. Allografts and Spinal Fusion. Int J Spine Surg 2021; 15:68.</a></li><li><a class="nounderline abstract_t">Hing KA, Wilson LF, Buckland T. Comparative performance of three ceramic bone graft substitutes. Spine J 2007; 7:475.</a></li><li><a class="nounderline abstract_t">Mendelson BC, Jacobson SR, Lavoipierre AM, Huggins RJ. The fate of porous hydroxyapatite granules used in facial skeletal augmentation. Aesthetic Plast Surg 2010; 34:455.</a></li><li><a class="nounderline abstract_t">Boden SD. Biology of lumbar spine fusion and use of bone graft substitutes: present, future, and next generation. Tissue Eng 2000; 6:383.</a></li><li><a class="nounderline abstract_t">An HS, Lynch K, Toth J. Prospective comparison of autograft vs. allograft for adult posterolateral lumbar spine fusion: differences among freeze-dried, frozen, and mixed grafts. J Spinal Disord 1995; 8:131.</a></li><li><a class="nounderline abstract_t">Musante DB, Firtha ME, Atkinson BL, et al. Clinical evaluation of an allogeneic bone matrix containing viable osteogenic cells in patients undergoing one- and two-level posterolateral lumbar arthrodesis with decompressive laminectomy. J Orthop Surg Res 2016; 11:63.</a></li><li class="breakAll">Is bone formation by silicon-substituted calcium phosphates affected by materials rate of resorption? ORS 2012 Annual Meeting. http://www.ors.org/Transactions/58/0597.pdf (Accessed on December 06, 2021).</li><li><a class="nounderline abstract_t">Hing KA, Revell PA, Smith N, Buckland T. Effect of silicon level on rate, quality and progression of bone healing within silicate-substituted porous hydroxyapatite scaffolds. Biomaterials 2006; 27:5014.</a></li><li><a class="nounderline abstract_t">Bohner M. Silicon-substituted calcium phosphates - a critical view. Biomaterials 2009; 30:6403.</a></li><li><a class="nounderline abstract_t">Cameron K, Travers P, Chander C, et al. Directed osteogenic differentiation of human mesenchymal stem/precursor cells on silicate substituted calcium phosphate. J Biomed Mater Res A 2013; 101:13.</a></li><li><a class="nounderline abstract_t">Cottrill E, Pennington Z, Lankipalle N, et al. The effect of bioactive glasses on spinal fusion: A cross-disciplinary systematic review and meta-analysis of the preclinical and clinical data. J Clin Neurosci 2020; 78:34.</a></li><li><a class="nounderline abstract_t">Duan R, van Dijk LA, Barbieri D, et al. Accelerated bone formation by biphasic calcium phosphate with a novel sub-micron surface topography. Eur Cell Mater 2019; 37:60.</a></li><li><a class="nounderline abstract_t">van Dijk LA, Barrère-de Groot F, Rosenberg AJWP, et al. MagnetOs, Vitoss, and Novabone in a Multi-endpoint Study of Posterolateral Fusion: A True Fusion or Not? Clin Spine Surg 2020; 33:E276.</a></li><li><a class="nounderline abstract_t">Lehr AM, Oner FC, Delawi D, et al. Efficacy of a Standalone Microporous Ceramic Versus Autograft in Instrumented Posterolateral Spinal Fusion: A Multicenter, Randomized, Intrapatient Controlled, Noninferiority Trial. Spine (Phila Pa 1976) 2020; 45:944.</a></li><li><a class="nounderline abstract_t">Mobbs RJ, Maharaj M, Rao PJ. Clinical outcomes and fusion rates following anterior lumbar interbody fusion with bone graft substitute i-FACTOR, an anorganic bone matrix/P-15 composite. J Neurosurg Spine 2014; 21:867.</a></li><li><a class="nounderline abstract_t">Lauweryns P, Raskin Y. Prospective analysis of a new bone graft in lumbar interbody fusion: results of a 2- year prospective clinical and radiological study. Int J Spine Surg 2015; 9.</a></li><li class="breakAll">i-FACTOR Peptide Enhanced Bone Graft https://www.accessdata.fda.gov/cdrh_docs/pdf14/p140019d.pdf (Accessed on December 17, 2021).</li><li><a class="nounderline abstract_t">Lytle EJ, Lawless MH, Paik G, et al. The minimally effective dose of bone morphogenetic protein in posterior lumbar interbody fusion: a systematic review and meta-analysis. Spine J 2020; 20:1286.</a></li><li><a class="nounderline abstract_t">DiGiovanni CW, Lin SS, Baumhauer JF, et al. Recombinant human platelet-derived growth factor-BB and beta-tricalcium phosphate (rhPDGF-BB/β-TCP): an alternative to autogenous bone graft. J Bone Joint Surg Am 2013; 95:1184.</a></li><li><a class="nounderline abstract_t">Kumar P, Vinitha B, Fathima G. Bone grafts in dentistry. J Pharm Bioallied Sci 2013; 5:S125.</a></li><li><a class="nounderline abstract_t">Raghuram A, Singh A, Chang DK, et al. Bone Grafts, Bone Substitutes, and Orthobiologics: Applications in Plastic Surgery. Semin Plast Surg 2019; 33:190.</a></li><li><a class="nounderline abstract_t">Zipfel GJ, Guiot BH, Fessler RG. Bone grafting. Neurosurg Focus 2003; 14:e8.</a></li><li><a class="nounderline abstract_t">Cohen-Rosenblum A, Cui Q. Osteonecrosis of the Femoral Head. Orthop Clin North Am 2019; 50:139.</a></li><li><a class="nounderline abstract_t">Muratori F, Mondanelli N, Rizzo AR, et al. Aneurysmal Bone Cyst: A Review of Management. Surg Technol Int 2019; 35:325.</a></li><li><a class="nounderline abstract_t">Montgomery C, Couch C, Emory CL, Nicholas R. Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options. J Knee Surg 2019; 32:331.</a></li><li><a class="nounderline abstract_t">Deng AD, Innocenti M, Arora R, et al. Vascularized Small-Bone Transfers for Fracture Nonunion and Bony Defects. Clin Plast Surg 2020; 47:501.</a></li><li><a class="nounderline abstract_t">Rupp M, Biehl C, Budak M, et al. Diaphyseal long bone nonunions - types, aetiology, economics, and treatment recommendations. Int Orthop 2018; 42:247.</a></li><li><a class="nounderline abstract_t">van Vugt TA, Geurts J, Arts JJ. Clinical Application of Antimicrobial Bone Graft Substitute in Osteomyelitis Treatment: A Systematic Review of Different Bone Graft Substitutes Available in Clinical Treatment of Osteomyelitis. Biomed Res Int 2016; 2016:6984656.</a></li><li><a class="nounderline abstract_t">Azi ML, Aprato A, Santi I, et al. Autologous bone graft in the treatment of post-traumatic bone defects: a systematic review and meta-analysis. BMC Musculoskelet Disord 2016; 17:465.</a></li><li><a class="nounderline abstract_t">Zekry KM, Yamamoto N, Hayashi K, et al. Reconstruction of intercalary bone defect after resection of malignant bone tumor. J Orthop Surg (Hong Kong) 2019; 27:2309499019832970.</a></li><li><a class="nounderline abstract_t">Millikan PD, Karas V, Wellman SS. Treatment of osteonecrosis of the femoral head with vascularized bone grafting. Curr Rev Musculoskelet Med 2015; 8:252.</a></li><li><a class="nounderline abstract_t">Buser Z, Brodke DS, Youssef JA, et al. Allograft Versus Demineralized Bone Matrix in Instrumented and Noninstrumented Lumbar Fusion: A Systematic Review. Global Spine J 2018; 8:396.</a></li><li><a class="nounderline abstract_t">Jacobsen MK, Andresen AK, Jespersen AB, et al. Randomized double blind clinical trial of ABM/P-15 versus allograft in noninstrumented lumbar fusion surgery. Spine J 2020; 20:677.</a></li><li><a class="nounderline abstract_t">Buser Z, Brodke DS, Youssef JA, et al. Synthetic bone graft versus autograft or allograft for spinal fusion: a systematic review. J Neurosurg Spine 2016; 25:509.</a></li><li><a class="nounderline abstract_t">Licina P, Coughlan M, Johnston E, Pearcy M. Comparison of Silicate-Substituted Calcium Phosphate (Actifuse) with Recombinant Human Bone Morphogenetic Protein-2 (Infuse) in Posterolateral Instrumented Lumbar Fusion. Global Spine J 2015; 5:471.</a></li></ol></div><div id="topicVersionRevision">Topic 134456 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24865980" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Bone substitutes in orthopaedic surgery: from basic science to clinical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30633080" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Autograft, Allograft, and Bone Graft Substitutes: Clinical Evidence and Indications for Use in the Setting of Orthopaedic Trauma Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23242766" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Microstructure and chemistry affects apatite nucleation on calcium phosphate bone graft substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11716023" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Osteoinduction, osteoconduction and osseointegration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15539372" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bone repair in the twenty-first century: biology, chemistry or engineering?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19170097" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Temporal growth factor release from platelet-rich plasma, trehalose lyophilized platelets, and bone marrow aspirate and their effect on tendon and ligament gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15240135" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Growth factor combination for chondrogenic induction from human mesenchymal stem cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23247591" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Bone grafts, bone substitutes and orthobiologics: the bridge between basic science and clinical advancements in fracture healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12211667" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Injury to the lateral femoral cutaneous nerve during harvest of iliac bone graft, with reference to the size of the graft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29445947" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Bone graft materials for posterolateral fusion made simple: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26857241" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124070" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Variability across ten production lots of a single demineralized bone matrix product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32266283" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : In-vivo Performance of Seven Commercially Available Demineralized Bone Matrix Fiber and Putty Products in a Rat Posterolateral Fusion Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32266283" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : In-vivo Performance of Seven Commercially Available Demineralized Bone Matrix Fiber and Putty Products in a Rat Posterolateral Fusion Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31337109" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Phenotypic Characterization of Bone Marrow Mononuclear Cells and Derived Stromal Cell Populations from Human Iliac Crest, Vertebral Body and Femoral Head.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17469183" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24561556" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mesenchymal stem cells: immune evasive, not immune privileged.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24929059" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cellular bone matrices: viable stem cell-containing bone graft substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31157144" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Allogenic Stem Cells in Spinal Fusion: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31157144" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Allogenic Stem Cells in Spinal Fusion: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11847406" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Natural coral exoskeleton as a bone graft substitute: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34376497" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Allografts and Spinal Fusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17630146" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparative performance of three ceramic bone graft substitutes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20186415" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The fate of porous hydroxyapatite granules used in facial skeletal augmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10992434" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Biology of lumbar spine fusion and use of bone graft substitutes: present, future, and next generation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7606120" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Prospective comparison of autograft vs. allograft for adult posterolateral lumbar spine fusion: differences among freeze-dried, frozen, and mixed grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27233773" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Clinical evaluation of an allogeneic bone matrix containing viable osteogenic cells in patients undergoing one- and two-level posterolateral lumbar arthrodesis with decompressive laminectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27233773" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical evaluation of an allogeneic bone matrix containing viable osteogenic cells in patients undergoing one- and two-level posterolateral lumbar arthrodesis with decompressive laminectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16790272" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of silicon level on rate, quality and progression of bone healing within silicate-substituted porous hydroxyapatite scaffolds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19695699" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Silicon-substituted calcium phosphates - a critical view.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22733430" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Directed osteogenic differentiation of human mesenchymal stem/precursor cells on silicate substituted calcium phosphate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32331941" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The effect of bioactive glasses on spinal fusion: A cross-disciplinary systematic review and meta-analysis of the preclinical and clinical data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30687909" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Accelerated bone formation by biphasic calcium phosphate with a novel sub-micron surface topography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31977334" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : MagnetOs, Vitoss, and Novabone in a Multi-endpoint Study of Posterolateral Fusion: A True Fusion or Not?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32080013" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy of a Standalone Microporous Ceramic Versus Autograft in Instrumented Posterolateral Spinal Fusion: A Multicenter, Randomized, Intrapatient Controlled, Noninferiority Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25325176" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical outcomes and fusion rates following anterior lumbar interbody fusion with bone graft substitute i-FACTOR, an anorganic bone matrix/P-15 composite.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25709887" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prospective analysis of a new bone graft in lumbar interbody fusion: results of a 2- year prospective clinical and radiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25709887" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Prospective analysis of a new bone graft in lumbar interbody fusion: results of a 2- year prospective clinical and radiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32339767" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The minimally effective dose of bone morphogenetic protein in posterior lumbar interbody fusion: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23824386" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recombinant human platelet-derived growth factor-BB and beta-tricalcium phosphate (rhPDGF-BB/β-TCP): an alternative to autogenous bone graft.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23946565" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bone grafts in dentistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31384235" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Bone Grafts, Bone Substitutes, and Orthobiologics: Applications in Plastic Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15727429" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Bone grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30850073" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Osteonecrosis of the Femoral Head.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31476792" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Aneurysmal Bone Cyst: A Review of Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30449024" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Giant Cell Tumor of Bone: Review of Current Literature, Evaluation, and Treatment Options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32892797" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Vascularized Small-Bone Transfers for Fracture Nonunion and Bony Defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29273837" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diaphyseal long bone nonunions - types, aetiology, economics, and treatment recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26904683" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical Application of Antimicrobial Bone Graft Substitute in Osteomyelitis Treatment: A Systematic Review of Different Bone Graft Substitutes Available in Clinical Treatment of Osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27829447" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Autologous bone graft in the treatment of post-traumatic bone defects: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30879390" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reconstruction of intercalary bone defect after resection of malignant bone tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26068178" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Treatment of osteonecrosis of the femoral head with vascularized bone grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29977726" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Allograft Versus Demineralized Bone Matrix in Instrumented and Noninstrumented Lumbar Fusion: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32001384" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Randomized double blind clinical trial of ABM/P-15 versus allograft in noninstrumented lumbar fusion surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27231812" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Synthetic bone graft versus autograft or allograft for spinal fusion: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26682097" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Comparison of Silicate-Substituted Calcium Phosphate (Actifuse) with Recombinant Human Bone Morphogenetic Protein-2 (Infuse) in Posterolateral Instrumented Lumbar Fusion.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
